Pricing Log in Create free account
Friday 6 November 2026 Export EXEL’s income statement to Excel — free account

Exelixis, Inc.

EXEL Healthcare Biotechnology

Exelixis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 6.98% from fiscal 2024.

Revenue
+10.2%
EPS
+22.2%
Free cash flow
−4.83%

Quarter to September 2026, against a year earlier

69.96 1.25 +1.82%
Market cap
$16.8B
P/E
19.9×
Fwd P/E
20.2×
Dividend yield
—
F-score
7/9
Altman Z
12.68
Beneish M
−2.61
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Exelixis, Inc. (EXEL) SEC filings, changes and red flags

Red flags

Filings

Form Period Filed What it reports Flags
10-Q Oct 2, 2026 P1I2: 10 added · 3 removed · 57 modified
P2I1A: no material changes, the filing says
8-K Oct 29, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Sep 10, 2026 8.01 Other events
8-K Aug 31, 2026 8.01 Other events
10-Q Jul 3, 2026 P1I2: 5 added · 4 removed · 52 modified
P2I1A: no material changes, the filing says
8-K Aug 5, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K May 26, 2026 5.02 Departure or appointment of directors or officers; 5.07 Submission of matters to a vote of security holders; 9.01 Financial statements and exhibits Officer departure
10-Q Apr 3, 2026
8-K May 5, 2026 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
10-K Jan 2, 2026 1: 27 added · 23 removed · 115 modified
1A: 12 added · 3 removed · 68 modified
7: 33 added · 34 removed · 60 modified
8-K Feb 10, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 11, 2026 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Nov 4, 2025 5.02 Departure or appointment of directors or officers; 8.01 Other events
10-Q Oct 3, 2025
8-K Nov 4, 2025 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Aug 29, 2025 5.02 Departure or appointment of directors or officers
10-Q Jul 4, 2025
8-K Jul 28, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Apr 4, 2025
8-K May 13, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-K Jan 3, 2025
8-K Feb 11, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 12, 2025 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Sep 27, 2024
8-K Oct 29, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
10-Q Jun 28, 2024
8-K Aug 6, 2024 2.02 Results of operations and financial condition; 8.01 Other events; 9.01 Financial statements and exhibits
8-K Apr 30, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Feb 6, 2024 2.02 Results of operations and financial condition; 9.01 Financial statements and exhibits
8-K Jan 2, 2024 2.02 Results of operations and financial condition; 2.05 Costs of exit or disposal activities; 5.02 Departure or appointment of directors or officers; 8.01 Other events; 9.01 Financial statements and exhibits

From the company’s filings on sec.gov. Red flags are raised by rules over the filings’ own data and text; they are not investment advice.